Anti-angiogenesis: Biology is the foundation for therapy

Drug Discovery Today

Volumn 8, Issue 8, 2003, Pages 344-346

  Gerber, Hans Peter ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; BIOTECHNOLOGY; CHIMERA; CLINICAL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DNA MICROARRAY; IMAGING; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037446392     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02670-9     Document Type: Conference Paper

References (4)

1. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5:1999;1359-1364.
2. Malik, A.K. and Gerber, H.P. Targeting VEGF ligands and receptors in cancer. Targets (in press).
3. Luttun A., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 1:2002;1.
4. Hattori K., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8:2002;841-849.